Key result
Neuron-Restrictive Silencer Factor protects against heart failure progression by limiting myocyte GαO expression.
Why the study?
Multiple signaling pathways contribute to cardiac hypertrophy progression to heart failure and arrhythmias, involving GPCRs, kinases, phosphatases, and transcriptional modifiers.
Highlights multiple nodes in hypertrophy progression; leaves open dominant therapeutic targets in HF.
any signaling pathways have been implicated in the development and progression of cardiac hypertrophy to heart failure (HF) and arrhythmias.These include multiple GPCRs (G-protein-coupled receptors; eg, angiotensin II), kinases (PKA, PKC, CaMKII [Ca-calmodulin-dependent protein kinase]), phosphatases (eg, CaN [calcineurin]), and transcriptional modifiers (eg, NFATs, HDACs [histone deacetylases], MEF2, and GATA4) that drive structural remodeling and altered excitation-contraction coupling signaling to result in altered contraction/relaxation and electrophysiology.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied Heart failure. Neuron-Restrictive Silencer Factor was evaluated. Neuron-Restrictive Silencer Factor limits myocyte GαO expression and is protective in heart failure progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: